» Articles » PMID: 38672455

The Tumor Microenvironment: Signal Transduction

Overview
Journal Biomolecules
Publisher MDPI
Date 2024 Apr 27
PMID 38672455
Authors
Affiliations
Soon will be listed here.
Abstract

In the challenging tumor microenvironment (TME), tumors coexist with diverse stromal cell types. During tumor progression and metastasis, a reciprocal interaction occurs between cancer cells and their environment. These interactions involve ongoing and evolving paracrine and proximal signaling. Intrinsic signal transduction in tumors drives processes such as malignant transformation, epithelial-mesenchymal transition, immune evasion, and tumor cell metastasis. In addition, cancer cells embedded in the tumor microenvironment undergo metabolic reprogramming. Their metabolites, serving as signaling molecules, engage in metabolic communication with diverse matrix components. These metabolites act as direct regulators of carcinogenic pathways, thereby activating signaling cascades that contribute to cancer progression. Hence, gaining insights into the intrinsic signal transduction of tumors and the signaling communication between tumor cells and various matrix components within the tumor microenvironment may reveal novel therapeutic targets. In this review, we initially examine the development of the tumor microenvironment. Subsequently, we delineate the oncogenic signaling pathways within tumor cells and elucidate the reciprocal communication between these pathways and the tumor microenvironment. Finally, we give an overview of the effect of signal transduction within the tumor microenvironment on tumor metabolism and tumor immunity.

Citing Articles

UBE2J1 is identified as a novel plasma cell-related gene involved in the prognosis of high-grade serous ovarian cancer.

Tian Y, Dong R, Guan Y, Wang Y, Zhao W, Zhang J J Transl Med. 2025; 23(1):129.

PMID: 39876019 PMC: 11776235. DOI: 10.1186/s12967-025-06135-9.


Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.


Construction and verification of an innovative immune-related and hallmark gene sets prognostic model for bladder cancer.

Zhou X, Liu Y, Lv Z, Shen C, Yang S, Zhang Z Transl Cancer Res. 2024; 13(9):4639-4653.

PMID: 39430822 PMC: 11483368. DOI: 10.21037/tcr-24-327.

References
1.
Gorlach A, Bertram K, Hudecova S, Krizanova O . Calcium and ROS: A mutual interplay. Redox Biol. 2015; 6:260-271. PMC: 4556774. DOI: 10.1016/j.redox.2015.08.010. View

2.
Prior I, Hood F, Hartley J . The Frequency of Ras Mutations in Cancer. Cancer Res. 2020; 80(14):2969-2974. PMC: 7367715. DOI: 10.1158/0008-5472.CAN-19-3682. View

3.
Levental K, Yu H, Kass L, Lakins J, Egeblad M, Erler J . Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell. 2009; 139(5):891-906. PMC: 2788004. DOI: 10.1016/j.cell.2009.10.027. View

4.
Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

5.
Roehlecke C, Schmidt M . Tunneling Nanotubes and Tumor Microtubes in Cancer. Cancers (Basel). 2020; 12(4). PMC: 7226329. DOI: 10.3390/cancers12040857. View